“Men who experience biochemical recurrence after radical prostatectomy or radiation therapy should undergo PET scanning so that they can have specific targeted treatments administered to the site or sites of recurrence rather than [be treated] using the historical type of clinical parameters that we used in the past,” says Gerald L. Andriole, MD.
“We really have a pretty good understanding of the genomic landscape at the DNA/RNA level, both in non–muscle-invasive disease and muscle-invasive and metastatic disease,” says Seth P. Lerner, MD, FACS.
We have a lot of work to do to define how to optimize the integration of this therapy into what we call ‘advanced prostate cancer’,” says Michael J. Morris, MD.
“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.
“The SUO has never been stronger in its ability to deliver on clinical trials,” says Michael S. Cookson, MD, MMHC, FACS.
“The thought [for transperineal biopsy] is that if you can avoid introducing some rectal bacteria into the tissue, that we may be able to totally avoid or at least minimize the post-biopsy infections,” says Badar M. Mian, MD, FACS.
“I have no doubt that within 10 years…what we've been basing our treatment strategies and surveillance strategies of high-grade…papillary disease is still going to be there. But, in reality, we're really going to have a much better idea of individual risk stratification and characteristics of their tumors,” says Sam S. Chang, MD, MBA.
“We need to be aware of what patients are having to pay out of pocket, how it can impact their overall quality of life, [and] how can it impact their ability to pay for other necessities in life,” says Kelvin A. Moses, MD, PhD, FACS.
“We’re not doing enough lymph node dissections in upper tract disease,” says Siv Venkat, MD, FRCSC.
“The take-home message here is that adjuvant nivolumab improves disease-free survival in patients with muscle-invasive urothelial cancer at high risk for recurrence after surgery,” says Matthew D. Galsky, MD.
“We're really moving into not just these annual meetings, but we're going to have some programs throughout the year that will be targeted towards…really important, impactful research that comes out,” says Michael S. Cookson, MD, MMHC, FACS.
“We will also cover options for germline testing—different ways that tests can be ordered, panel options that are available commercially,” says Veda N. Giri, MD.
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.
“New regimens should now start to be explored, both…single-agent drugs as well as combination therapies,” says Pavlos Msaouel, MD, PhD.
“[Polygenic risk scores] will help augment PSA screening and other tools to really figure out when we should initiate prostate cancer screening in men and how frequently that screening should occur,” says Isla Garraway, MD, PhD.
“[It’s] important to see all of these…clinically important endpoints going in the same direction,” says Matthew D. Galsky, MD.
“I think this is an area that needs to be really personalized to each clinical practice,” says Alicia K. Morgans, MD, MPH.
“It was incredibly humbling,” says Eila C. Skinner, MD.
“Our data suggests that we shouldn’t just be relying on metastasis-directed therapy alone,” says Andrew J. Armstrong, MD, MSc.
Vivek K. Narayan, MD, MS, provides insight on the evolution of care for mCSPC and the current use of ARI-directed therapy for disease management.
Experts in prostate cancer comment on the role of urologists in performing molecular testing and share how they facilitate treatment of advanced prostate cancer across multiple disciplines.
“This category of therapeutic is fairly well-tolerated; safe to give,” says Mohummad M. Siddiqui MD.
“We still debate and there’s some good data that [supports that] chemotherapy is not that effective for patients with penile cancer,” says Philippe E. Spiess, MD, MS, FACS.
“Adverse pathology is a clear predictor of long-term outcomes for patients,” says Eric A. Klein, MD.
“We’re just getting one step closer to being able to find urine tests that we can use to help risk stratify patients, and then help understand the genetic profiles of other tumors, which might help guide management later on,” says Wesley Yip, MD.
“We found that, overall, segmental ureterectomy patients actually did better in terms of overall survival,” says Siv Venkat, MD, FRCSC.
“It’s really important to look at the pathology we’ve learned before considering these patients for active surveillance treatment,” says Isla Garraway, MD, PhD.
"The results of this trial impacted practice globally,” says Michael J. Morris, MD.
“For most men, we can identify the specific site or sites of recurrence, and thereby use a more directed therapy that specifically targets the abnormal sites,” says Gerald L. Andriole, MD.
